Puresta launches EVERQ, AI-powered skin-health platform

Puresta Lifestyle Private Limited announced the launch of EVERQ, an AI-powered skin-health platform designed to bring skin assessment, dermatologist consultations, personalised treatment and ongoing skincare together in one connected journey.

EVERQ is part of Puresta’s integrated skin-health ecosystem, which also includes SKINQ Rx and SKINQ. EVERQ serves as the consumer-facing platform connecting AI-led skin assessment with dermatologist-led care. SKINQ Rx provides targeted, dermatologist-led treatment solutions based on the consultation, while SKINQ extends the experience into clinically validated everyday and maintenance skincare.

The platform is being developed with a focus on Indian and melanin-rich skin, recognising that concerns such as pigmentation, acne, sensitivity and post-inflammatory marks can present differently across skin types. Puresta combines technology, dermatological expertise and data-led formulation as part of its approach to personalised skin health, with a focus on moving consumers away from generic product recommendations and towards solutions based on their individual skin needs.

With EVERQ, Puresta aims to move skincare from a primarily product-led experience towards a more personalised and outcome-led model. Rather than treating a consultation, prescription and skincare purchase as separate transactions, the platform is designed to retain context across the consumer’s care journey. As a consumer’s skin changes, the care journey can evolve with it.

The digital-first model also aims to make dermatologist-led skincare more accessible beyond India’s largest cities, reducing geography as a barrier to professional skin care.

Hitaysh Dhingraa, co-founder & CEO, Puresta, said: “India doesn’t have a skincare discovery problem. It has a diagnosis problem. Consumers have thousands of products and millions of recommendations, but very little clarity on what their skin actually needs. We built EVERQ around a simple philosophy — Diagnose First. Then Treat. AI helps us understand consumers and their skin at scale, dermatologists bring clinical judgement, and our ecosystem helps take that care from assessment through treatment and ongoing skincare. We don’t want to sell consumers more skincare. We want to help them use the right skincare.”

  • Related Posts

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    This World Mental Health Day (10th October), six mental health and medical organisations from India and the United Kingdom- India Mental Health Alliance (IMHA), the Indian Psychiatric Society (IPS), Indian…

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

    According to official sources in the Department of Pharmaceuticals, the new measure is expected to result in reductions of up to 70% in the MRP of certain cancer medicines. The…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

    Gujarat FDCA cracks down on four firms for illegal drug sale; cancels licences of two

    Gujarat FDCA cracks down on four firms for illegal drug sale; cancels licences of two

    9,800 psychotropic tablets worth ₹2.53 crore seized in Mumbai’s Govandi

    9,800 psychotropic tablets worth ₹2.53 crore seized in Mumbai’s Govandi

    Story of Bariatric Surgery Joining One Family’s Battle Against Severe Obesity

    Story of Bariatric Surgery Joining One Family’s Battle Against Severe Obesity

    Maharashtra FDA Cancels Three Cadila Pharma Licences Over Aciloc, Aciloc+ Drug Mix-Up Risk

    Maharashtra FDA Cancels Three Cadila Pharma Licences Over Aciloc, Aciloc+ Drug Mix-Up Risk